Clinical Trials Browser

Interventional × Hemangiosarcoma × spartalizumab × Clear all

NCT03860272 2025-02-06

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT05961761 2023-07-27

PROPANE

Phase 2 Recruiting

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2 Withdrawn

Hemangiosarcoma